The Business Wire link quotes Gilead’s CEO as saying:
“Today’s approval represents a
significant advance for patients with HCV
genotypes 2 and 3, who previously required more complex and costly regimens,” said John Milligan, Ph.D., President and Chief Executive Officer of Gilead. “As
the first and only pan-genotypic cure for hepatitis C, Epclusa has the potential to eliminate the need for genotype testing, which can be a barrier to treatment in certain resource-constrained settings. We look forward to making Epclusa available to patients around the world as quickly as possible.” See:
www.businesswire.com/news/home/201606280...es-Gilead’s-Epclusa®
Generic Darvoni (SOF 400mg + DCV 60mg) was the
first and only pan-genotypic cure for HCV(until now), see:
fixhepc.com/forum/media-news/1053-darvoni-story.html
Therefore, Epclusa (SOF + VEL) is the
second pan-genotypic cure … the first to be FDA approved … only because Gilead (SOF) and Bristol-Myres Squibb (DCV) didn’t want to work together and share profits. It’s all about trying to corner the market with a one pill cure all. In other words, it’s all about maximising profits, NOT about maximising the number of HCV sufferers being cured.
Epclusa may be an advancement for difficult to cure GT3s, however, it is
NOT a significant advancement for
GT2s who have a very high clearance rate taking Generic SOF + DCV on this forum. All you need is Darvoni for approximately USD700 + shipping & handling for a 12 week treatment. See:
www.darvoni.com/
Knowledge is power. Knowledge shared is power multiplied.”
Robert Noyce
Cheers
GT2
1983: Hospitalised with Acute non-A, non-B Hepatitis after ICU blood transfusion 3mths earlier => HCV GT2
22/02/16: (pre-tmt) ALT 61, VL 2.48 IU/ml Hepascore 0.32 (F1/2), fatigue, brain fog, bloating (Treatment Naïve)
10/04/16: (Start tmt) Sofovir +DaclaHep (SOF + DCV) by Hetero Labs in India
09/05/16: ALT 34, VL:
NOT Detected

, FBG 11.9

17/6/16 FBG 5.7; PPBG (@14.22) 6.9 (@ 20.45) 7.1; BP 124/72

(Accu-Chek Mobile & Omron Auto BP Monitor)
